SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination

Jose Alfredo Samaniego Castruita; Uffe Vest Schneider; Sarah Mollerup; Thomas Daell Leineweber; Nina Weis; Jens Bukh; Martin Schou Pedersen; Henrik Westh

doi:10.1111/apm.13294

SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination

Jose Alfredo Samaniego Castruita, Uffe Vest Schneider, Sarah Mollerup, Thomas Daell Leineweber, Nina Weis, Jens Bukh, Martin Schou Pedersen, Henrik Westh^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

30 Citations (Scopus)

20 Downloads (Pure)

Abstract

In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has been with the Pfizer-BioNTech (BTN162b2) or the Moderna (mRNA-1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to the Danish roll-out vaccination plan. To monitor HCV infection, RNA was extracted from patient plasma and RNA sequencing was performed on the Illumina platform. In 10 of 108 HCV patient samples, full-length or traces of SARS-CoV-2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID-19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid-nanoparticles and the half-life of these and mRNA vaccines in humans.

Original language	English
Journal	APMIS
Volume	131
Issue number	3
Pages (from-to)	128-132
Number of pages	5
ISSN	0903-4641
DOIs	https://doi.org/10.1111/apm.13294
Publication status	Published - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.

Keywords

blood
Hepatitis C virus
mRNA
SARS-CoV-2
vaccine

Access to Document

10.1111/apm.13294Licence: CC BY-NC-ND

FulltextFinal published version, 447 KBLicence: CC BY-NC-ND

Cite this

@article{cd906ae0188b45d29c3d32fe6afd5be5,

title = "SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination",

abstract = "In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has been with the Pfizer-BioNTech (BTN162b2) or the Moderna (mRNA-1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to the Danish roll-out vaccination plan. To monitor HCV infection, RNA was extracted from patient plasma and RNA sequencing was performed on the Illumina platform. In 10 of 108 HCV patient samples, full-length or traces of SARS-CoV-2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID-19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid-nanoparticles and the half-life of these and mRNA vaccines in humans.",

keywords = "blood, Hepatitis C virus, mRNA, SARS-CoV-2, vaccine",

author = "Castruita, {Jose Alfredo Samaniego} and Schneider, {Uffe Vest} and Sarah Mollerup and Leineweber, {Thomas Daell} and Nina Weis and Jens Bukh and Pedersen, {Martin Schou} and Henrik Westh",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.",

year = "2023",

doi = "10.1111/apm.13294",

language = "English",

volume = "131",

pages = "128--132",

journal = "APMIS",

issn = "0903-4641",

publisher = "Wiley Online",

number = "3",

}

TY - JOUR

T1 - SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination

AU - Castruita, Jose Alfredo Samaniego

AU - Schneider, Uffe Vest

AU - Mollerup, Sarah

AU - Leineweber, Thomas Daell

AU - Weis, Nina

AU - Bukh, Jens

AU - Pedersen, Martin Schou

AU - Westh, Henrik

PY - 2023

Y1 - 2023

N2 - In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has been with the Pfizer-BioNTech (BTN162b2) or the Moderna (mRNA-1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to the Danish roll-out vaccination plan. To monitor HCV infection, RNA was extracted from patient plasma and RNA sequencing was performed on the Illumina platform. In 10 of 108 HCV patient samples, full-length or traces of SARS-CoV-2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID-19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid-nanoparticles and the half-life of these and mRNA vaccines in humans.

AB - In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has been with the Pfizer-BioNTech (BTN162b2) or the Moderna (mRNA-1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to the Danish roll-out vaccination plan. To monitor HCV infection, RNA was extracted from patient plasma and RNA sequencing was performed on the Illumina platform. In 10 of 108 HCV patient samples, full-length or traces of SARS-CoV-2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID-19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid-nanoparticles and the half-life of these and mRNA vaccines in humans.

KW - blood

KW - Hepatitis C virus

KW - mRNA

KW - SARS-CoV-2

KW - vaccine

U2 - 10.1111/apm.13294

DO - 10.1111/apm.13294

M3 - Journal article

C2 - 36647776

AN - SCOPUS:85146942614

SN - 0903-4641

VL - 131

SP - 128

EP - 132

JO - APMIS

JF - APMIS

IS - 3

ER -